公开(公告)号：EP2155861A1

公开(公告)日：2010-02-24

申请号：EP08742643.3

申请日：2008-04-07

申请人： International Stem Cell Corporation

发明人： REVAZOVA, Elena, S. ,  TUROVETS, Nikolay, A. ,  KUZMICHEV, Leonid, N. ,  JANUS, Jeffrey, D.

IPC分类号： C12N5/08

CPC分类号： C12N5/0606 ,  A61K35/545 ,  C12N5/0609 ,  C12N2500/02 ,  C12N2500/14 ,  C12N2501/115 ,  C12N2501/235 ,  C12N2502/1323

摘要： Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.

公开(公告)号：EP2155861B1

公开(公告)日：2018-09-05

申请号：EP08742643.3

申请日：2008-04-07

申请人： International Stem Cell Corporation

发明人： REVAZOVA, Elena, S. ,  TUROVETS, Nikolay, A. ,  KUZMICHEV, Leonid, N. ,  JANUS, Jeffrey, D.

IPC分类号： C12N5/0735

CPC分类号： C12N5/0606 ,  A61K35/545 ,  C12N5/0609 ,  C12N2500/02 ,  C12N2500/14 ,  C12N2501/115 ,  C12N2501/235 ,  C12N2502/1323

摘要： Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.